Glenmark Expands Oncology Portfolio ,Signs Exclusive Global Licensing Deal With Hansoh Pharma To Commercialise EGFR-TKI Aumolertinib; Covering Multiple Regions

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has entered into an exclusive license, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. for aumolertinib, a third-generation EGFR tyrosine kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC). Under the agreement, Glenmark gains exclusive rights to develop and commercialise the therapy across multiple international markets.

The licensed territories include the Middle East and Africa, Southeast and South Asia, Australia, New Zealand, Russia and the CIS region, as well as selected Caribbean countries. Hansoh Pharma will receive an upfront payment in the low double-digit million-dollar range, along with potential regulatory and commercial milestone payments that could exceed USD 1 billion. The agreement also includes tiered royalties based on net sales in the licensed regions.

“At Glenmark, we remain focused on building a growth-oriented oncology business across high-potential markets. Aumolertinib is a strategic addition that strengthens our near-term commercial pipeline and enhances our ability to serve patients with EGFR-mutated lung cancer. This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd.

Aumolertinib is already marketed as Ameile® in China and as Aumseqa® in the United Kingdom and Europe. As a monotherapy, it has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations, as well as for patients with EGFR T790M mutation-positive disease. In China, the therapy has been approved for four indications spanning first-line, second-line, adjuvant, and post-chemoradiotherapy settings.

Notably, aumolertinib represents China’s first original third-generation EGFR-TKI to be launched internationally and was Hansoh Pharma’s first innovative drug approved outside China. With multiple approvals across disease stages and treatment lines, the collaboration aims to expand global access to this targeted therapy for patients with EGFR-mutated NSCLC.